Clinical Trial Search

Primary: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene — 3.69; 4.13; 3.82; 0.38 percent change — p=<0.05

Primary: Time-weighted Averages of Mean Arterial Pressure — 87.40; 87.36 mmHg

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants

Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine — 2.13; 2.08 percent change — p=0.002

Primary: Pharmacokinetics (PK): Dose Normalized Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Evacetrapib — 111; 248…

Primary: Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM) — 0.822; 0.846 ratio

Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 1; 2 Participants

Primary: Area Under the Plasma Concentration-time Curve (AUC) Over One Dosing Interval for Diclofenac at Steady State (AUC0-τ,ss) (τ = 12 Hours) (Day 7) — 46.855; 40.175; 83.644…

Primary: Cohort 1: Skin Irritation Index — 40.0; 5.0 scores on a scale

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 0; 0; 0; 0 Participants

Primary: Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro — 677.84; 716.52…

Primary: Number of Patients With Treatment-emergent Adverse Events — 4; 3; 0; 1 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) — 1634 ng/mL

Primary: Area Under Plasma Concentration-time at Time t (AUC0-t) — 915; 909 h*μg/mL

Primary: Number of Participants Experiencing an Adverse Event (AE) — 1; 5; 1 Participants